Meta description: A regulatory update on the Moni Patch validation study for febrile patients, detailing status sponsorship and implications for device safety and efficacy.
The Moni Patch Temperature Monitoring Patch System advances to a clinical accuracy validation focused on febrile patients. The study status is Not yet recruiting. Sponsors are Murata Vios, Inc. and Sonoma State University. The intervention is a patch based temperature monitoring device used to track body temperature. The evaluation aims to generate accuracy data under conditions common in fever and to identify potential device related factors that could affect readings. The registry entry provides a formal record of the research intention and supports regulatory transparency.
What changed in the Moni Patch validation study?
The ClinicalTrials.gov record NCT07397078 now states Not yet recruiting, signaling the study has not begun enrollment. The focus is on body temperature monitoring in febrile conditions using the Moni Patch System. Sponsor organizations are Murata Vios, Inc. and Sonoma State University. The change formalizes the study description and makes plans for data collection and analysis more transparent to regulators and clinicians. The registry entry also helps coordinate sponsor and academic activities by aligning milestones with regulatory expectations and quality management processes.
What is known about study design and sponsor roles?
From the source text the intervention is the Moni Patch Temperature Monitoring Patch System. Collaboration between a private company and an academic partner indicates a collaborative approach to evaluating accuracy and safety endpoints in a defined population. The design will consider enrolment criteria, monitoring duration, reference temperature standards and predefined performance endpoints to guide future reporting. The involvement of an academic partner supports independent data integrity and methodological rigor consistent with regulatory expectations.
Why is this validation important for febrile patient care and regulatory oversight?
Accurate temperature readings are essential for febrile care, triage and treatment decisions. A robust clinical accuracy validation supports labeling and risk management under regulatory expectations. Not yet recruiting means wait for data before conclusions can be drawn. The listing on ClinicalTrials.gov provides a transparent source for regulators, clinicians, and quality teams. For clinicians the results may influence interpretation of patch based readings during fever and contribute to best practice guidance in clinical workflows.
What regulatory backdrop applies to temperature monitoring devices?
Under MDR requirements the manufacturer must present the intended use, performance characteristics, and safety profile. For a patch based monitor, evidence of accuracy, stability and data integrity will support future regulatory submissions both in the EU and other markets. Sponsor statements in the listing are provided as part of the registry description. The announcement demonstrates a commitment to evidence generation that supports ongoing risk management and post market surveillance activities.
What is the Moni Patch System and what does validation seek to verify?
The Moni Patch is a patch based temperature monitoring device. The validation aims to quantify accuracy against reference standards and characterize performance in real world fever states. The Not yet recruiting status indicates enrollment and data collection have not yet started, so regulatory decisions will await the study’s progression. The study will likely compare readings against calibrated thermometers and consider time to fever detection as a potential endpoint for performance assessment.
What endpoints and safety considerations are contemplated?
Expected endpoints include measurement accuracy, time to fever detection, skin safety and patch adhesion. Considerations cover data integrity and software components that influence clinical decisions. Findings will inform risk management and labeling strategies in future submissions. The study design will also address potential device related adverse events such as skin irritation or sensor drift and will note if any discontinuations occur.
What are the implications for safety, performance and postmarket planning?
Results from this trial will influence the device’s safety profile and performance claims. Regulators and manufacturers will assess whether the Moni Patch meets regulatory expectations for medical devices that guide temperature related decisions. A collaboration with an academic partner strengthens the evidentiary basis for future regulatory filings and potential market adoption. If data show high accuracy and stable readings, this could support stronger labeling and integration into clinical workflows with appropriate risk controls.
How will updates be communicated?
Regulatory bodies and sponsors typically share recruitment status, endpoints, and results via registry postings and official communications. The ClinicalTrials.gov listing is a primary source for status updates and data releases. Stakeholders should expect periodic updates as milestones are completed and as analytic plans are finalized.
How can stakeholders stay informed and what are the next steps?
Stakeholders should monitor the ClinicalTrials.gov page and sponsor announcements for recruitment updates, endpoint definitions and study results. As enrollment proceeds, accuracy and safety data will inform risk management plans and potential labeling changes. The evidence generated may influence future regulatory submissions and the adoption of the patch based monitor in fever management protocols.
Who should care?
Clinical teams, regulatory and quality professionals, and device manufacturers involved in body temperature monitoring should track this study for potential changes in guidance and performance expectations. The collaboration between industry and academia highlights the importance of independent data integrity and transparent reporting for regulatory compliance and patient safety.
FAQ
- Question 1: What is the Moni Patch System?
Answer: It is a patch based temperature monitoring device used to track body temperature in febrile conditions.
- Question 2: What is the status of the study?
Answer: Not yet recruiting.
- Question 3: Who sponsors the study?
Answer: Murata Vios, Inc. and Sonoma State University.
- Question 4: Where can I find more information?
Answer: ClinicalTrials.gov listing NCT07397078 on the registry.
In summary the Moni Patch accuracy validation is in early stages with Not yet recruiting status. Regulators and stakeholders should monitor the ClinicalTrials.gov listing for updates. The outcome may influence regulatory submissions and device labeling for febrile care.
Disclaimer: This content is for professionals and is not legal advice. It is informational only and not a substitute for regulatory counsel or official MDR guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07397078?term=medical+device